

November 14, 2024

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Thursday, November 14, 2024

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we Zota Health Care Limited (“the Company”) would like to inform you that the Board of Directors of the Company in its Meeting held on Thursday, November 14, 2024 at 02:00 P.M. at Zota House, Bhagwan Aiyappa Complex, Next to Batliboi, Udhna-Navsari State Highway, Surat – 394210, Gujarat, have inter alia, discussed and approved the following business:

1. Considered and approved standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2024 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (**Annexure –1**).

The unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company’s website at www.zotahealthcare.com

The Board meeting concluded at 7:00 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat
Encl: a/a

Registered Office:

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Zota Health Care Limited

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Zota Health Care Limited** (the "Company") **for the quarter and half year ended September 30, 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

Management's Responsibility

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

Pradeep K Singhi & Associates

CHARTERED ACCOUNTANTS

Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W**

**Date: 14/11/2024
Place: Surat**

**Pradeep Kumar Singhi
(Partner)
M. No. 200/024612
UDIN: 24024612BKATJI5171**

A/401, President Plaza, Near R.T.O. Office, Ring Road, Surat -395001

PH. No. 2474714 / 2474954 E-mail: info.surat@pradeepsinghi.com

healthcare ltd. Particulars		Quarter Ended			Half Year Ended		Year Ended
		30-09-2024 (Unaudited)	30-06-2024 (Unaudited)	30-09-2023 (Unaudited)	30-09-2024 (Unaudited)	30-09-2023 (Unaudited)	31-03-2024 (Audited)
I.	Revenue from Operations	5900.92	5220.36	4115.01	11121.28	7640.08	16658.50
II.	Other Income	97.01	46.88	62.51	143.89	98.06	205.19
III.	Total Income	5997.93	5267.25	4177.52	11265.17	7738.14	16863.69
IV.	Expenses:						
	Cost of Materials Consumed	430.72	279.11	320.49	709.83	583.18	1277.46
	Purchases of Stock-in-Trade	2907.89	2344.68	1611.47	5252.57	3599.66	9520.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	215.20	560.23	618.95	775.43	743.07	(352.67)
	Employee Benefit Expenses	729.09	644.17	478.27	1373.26	855.82	1997.36
	Finance Costs	51.91	41.92	24.96	93.84	29.62	36.47
	Depreciation / Amortisation and Depletion Expense	73.35	67.64	76.68	141.00	131.76	300.73
	Other Expenses	1293.73	1097.29	775.99	2391.02	1486.97	3593.37
	Total Expenses	5701.91	5035.03	3906.81	10736.94	7430.09	16373.07
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	296.02	232.21	270.70	528.23	308.05	490.61
VI.	Exceptional Items	-	-	-	-	-	-
VII.	Profit/(loss) before tax	296.02	232.21	270.70	528.23	308.05	490.61
VIII.	Tax Expense:						
	(1) Current tax	84.74	64.71	75.49	149.45	88.45	153.08
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(6.28)
	(2) Deferred Tax	23.91	(9.07)	(16.45)	14.84	(19.61)	(5.82)
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	235.19	158.43	178.76	393.62	199.98	337.99
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII.	Profit/ (Loss) for the period	235.19	158.43	178.76	393.62	199.98	337.99
XIV.	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Statement of profit and loss	(20.58)	10.62	46.59	(9.96)	26.24	19.82
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	5.18	(2.67)	(11.72)	2.51	(6.60)	(4.99)
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
	Other comprehensive income for the period, net of tax	(15.40)	7.94	34.86	(7.46)	19.64	14.83
	Total comprehensive income for the period (XIII + XIV)	219.79	166.37	213.62	386.17	219.62	352.82
	Paid-up Equity Share Capital	2740.76	2653.43	2584.73	2740.76	2584.73	2584.73
	Other Equity						9592.80
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (in ₹)	0.89	0.60	0.70	1.48	0.79	1.32
	(2) Diluted (in ₹)	0.82	0.60	0.68	1.38	0.77	1.29

* denotes figures less than a lakh
For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625219)


Company Secretary
Ashvin Variya


Chief Financial Officer
Viral Mandviwala



For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Date: 14-11-2024
Place : Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

**The Board of Directors of
Zota Health Care Limited**

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the **quarter and half year ended September 30, 2024** ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").

Management's Responsibility

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

Auditor's Responsibility

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

- a. Zota Health Care Limited (Parent)

CHARTERED ACCOUNTANTS

- b. Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
- c. Davaindia Health Mart Limited (Wholly Owned Subsidiary)
- d. Zota Nex Tech Limited (Wholly Owned Subsidiary)
- e. Everyday Herbal Beauty Care Private Limited (Subsidiary)
- f. Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

Conclusion

Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters

We did not review the interim financial statements of the subsidiaries included in the consolidated unaudited financial results that reflect total assets of Rs. 18399.94 Lakhs as at September 30, 2024, total revenues of Rs. 2601.80 Lakhs and Rs.4583.30 Lakhs, total net loss of Rs. 1442.81 Lakhs and Rs.2826.66 Lakhs and total comprehensive loss of Rs. 1332.44 Lakhs and Rs.2697.38 Lakhs, respectively for the quarter and half year ended September 30, 2024, and net cash flows of Rs. 96.71 Lakhs for the half year ended September 30, 2024 as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

Date: 14/11/2024

Place: Surat


Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

UDIN: 24024612BKATJJ8840

healthcare ltd. Particulars		Quarter Ended			Half Year ended		Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from Operations	6727.58	5630.06	4527.32	12357.65	8392.14	18048.85
II.	Other Income	54.27	1.79	39.60	56.06	54.80	115.61
III.	Total Income	6781.86	5631.85	4566.93	12413.71	8446.94	18164.46
IV.	Expenses:						
	Cost of Materials Consumed	430.72	279.11	320.49	709.83	583.18	1277.46
	Purchases of Stock-in-Trade	2905.91	2321.63	1611.47	5227.53	3599.66	9520.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(211.11)	33.36	553.04	(177.75)	670.82	(1127.79)
	Employee Benefit Expenses	2006.36	1624.65	598.29	3631.01	1057.90	3045.05
	Finance Costs	285.33	289.80	113.61	575.13	196.86	478.82
	Depreciation / Amortisation and Depletion Expense	951.23	802.35	479.92	1753.58	820.71	2008.51
	Other Expenses	1682.72	1497.20	1001.27	3179.91	1909.95	4578.35
	Total Expenses	8051.15	6948.09	4678.09	14899.25	8839.07	19780.75
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	(1269.30)	(1216.24)	(111.17)	(2485.54)	(392.14)	(1616.29)
VI.	Exceptional Items	0.00	-	-	-	-	-
VII.	Profit/(loss) before tax	(1269.30)	(1216.24)	(111.17)	(2485.54)	(392.14)	(1616.29)
VIII.	Tax Expense:						
	(1) Current tax	84.74	64.71	75.49	149.45	88.45	153.08
	(1.1) I.T. & DD Tax Provision Created Short/ excess	-	-	-	-	-	(6.28)
	(2) Deferred Tax	135.94	8.57	21.26	144.51	31.41	328.31
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1218.10)	(1272.39)	(165.40)	(2490.49)	(449.18)	(1434.79)
X.	Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XI.	Tax Expense of discontinued Operations	-	-	-	-	-	-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)	-	-	-	-	-	-
XIII.	Profit/ (Loss) for the period	(1218.10)	(1272.39)	(165.40)	(2490.49)	(449.18)	(1434.79)
XIV.	Other Comprehensive Income						
	A (i) Items that will not be reclassified to Statement of profit and loss	(22.78)	12.39	47.40	(10.39)	27.15	24.59
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	5.73	(3.12)	(11.93)	2.62	(6.83)	(6.18)
	B (i) Items that will be reclassified to Statement of profit and loss	(0.01)	(0.06)	0.02	(0.07)	(0.03)	(0.07)
	(ii) Income Tax relating to items that will be reclassified to profit and loss	*	0.01	*	0.02	*	0.02
	Other comprehensive income for the period, net of tax	(17.06)	9.23	35.49	(7.83)	20.30	18.36
	Total comprehensive income for the period (XIII + XIV)	(1235.16)	(1263.16)	(129.91)	(2498.32)	(428.88)	(1416.42)
	Profit attributable to:						
	Owners of the parent	(1210.24)	(1272.39)	(165.40)	(2482.63)	(449.18)	(1434.79)
	Non-controlling interest	(7.86)	-	-	(7.86)	-	-
	Other comprehensive income attributable to:						
	Owners of the parent	(17.06)	9.23	35.49	(7.83)	20.30	18.36
	Non-controlling interest	-	-	-	-	-	-
	Total Comprehensive Income attributable to:						
	Owners of the parent	(1227.30)	(1263.16)	(129.91)	(2490.46)	(428.88)	(1416.42)
	Non-controlling interest	(7.86)	-	-	(7.86)	-	-
	Paid-up Equity Share Capital	2740.76	2653.43	2584.73	2740.76	2584.73	2584.73
	Other Equity	-	-	-	-	-	6412.92
	Earnings per equity share of face value of ₹ 10 each						
	(1) Basic (in ₹)	(4.57)	(4.80)	(0.64)	(9.36)	(1.77)	(5.59)
	(2) Diluted (in ₹)	(4.23)	(4.80)	(0.63)	(8.69)	(1.73)	(5.47)

* denotes figures less than a lakh

For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)



(Managing Director)
Moxesh K. Zota
(Din : 07625219)





Company Secretary
Ashvin Variya
Date: 14-11-2024
Place : Surat



Chief Financial Officer
Viral Mandviwala

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

1. The above financial results for the quarter and half year ended September 30, 2024 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on November 14, 2024.
2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.
3. The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2024.
4. During the quarter, the Company has issued and allotted 8,73,294 equity shares of Rs. 10/- each on a preferential basis at Rs. 509/- per equity share on August 14, 2024.
5. The Company has during the quarter issued and allotted 26,44,836 Fully convertible warrants each convertible into equivalent number of fully paid up equity share of the Company of face value of Rs.10/- each on a preferential basis at Rs. 509/- per warrant on August 14, 2024 upon receipt of the upfront money Rs. 3365.55 lakhs being 25% of warrant issue price (i.e. Rs. 127.25) per warrant. Balance 75% of warrant issue price (i.e. Rs. 381.75) per warrant shall be payable within 18 months from the date of allotment on exercise of rights attached to the warrants.
6. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.
7. The consolidated results include the result of following companies:
 - A) Wholly owned subsidiaries:
 - i) Zota Healthcare Lanka (Pvt) Ltd
 - ii) Davaindia Health Mart Limited
 - iii) Zota Nex Tech Limited
 - B) Subsidiaries:
 - i) Everyday Herbal Beauty Care Private Limited
 - ii) Everyday Herbal Beauty And Wellness Care Private Limited
8. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 9552.30 lakhs and a corresponding Lease Liability of Rs. 10462.04 lakhs as at September 30, 2024. The impact of this on the consolidated profit for the quarter and half year ended September 30, 2024 is Rs. 142.23 lakhs and Rs. 324.84 lakhs respectively.
9. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.



Registered Office :

Zota House, 2/396, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

healthcare ltd.	PARTICULARS	Consolidated		Standalone	
		Half year ended 30-09-2024 (Unaudited)	Half year ended 30-09-2023 (Unaudited)	Half year ended 30-09-2024 (Unaudited)	Half year ended 30-09-2023 (Unaudited)
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit Before Tax as per Statement of Profit and Loss	-2485.54	-392.14	528.23	308.05
	Adjusted for:				
	Exceptional items		-		
	Depreciation / Amortisation and Depletion Expense	1753.58	820.71	141.00	131.76
	Employee stock option expense	28.45	-	28.45	-
	Interest on Fixed Deposits	-47.65	-44.35	-135.48	-88.98
	Finance Costs	462.93	185.37	26.77	23.28
	Operating Profit before Working Capital Changes	-288.22	569.59	588.96	374.10
	Adjusted for:				
	Trade Payables	-356.79	-947.07	415.94	-949.20
	Provisions-Current Liabilities	543.77	195.09	246.04	162.81
	Provisions - Non-Current	104.51	30.59	35.29	24.67
	Current Liabilities	137.34	631.92	101.89	662.71
	Trade Receivables	-164.43	-442.73	-373.39	-1420.31
	Loans	218.60	-264.84	-1323.09	-139.18
	Inventories	-1091.45	608.39	624.42	680.64
	Other Current Assets	-109.34	-63.60	-113.77	108.47
	Changes in Working Capital	-717.79	-252.26	-3748.67	-869.40
	Cash Generated from Operations	-1006.01	317.34	-3159.71	-495.29
	Taxes Paid	-146.84	-95.29	-146.95	-95.06
	Net Cash Flow from/(Used in) Operating Activities (A)	-1152.85	222.05	-3306.65	-590.35
B	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Intangible Assets	-67.01	-34.21	-67.01	-34.21
	Decrease in Long Term Loans & Advances	-	-	-160.87	-40.17
	Interest on Fixed Deposits	47.65	44.35	135.48	88.98
	Interest - others	-26.77	-23.28	-26.77	-23.28
	Proceeds from disposal of Property, Plant and Equipment and Intangible Assets	-	-	-	-
	Purchase of Tangible Assets	-1511.42	-491.55	-57.41	-297.84
	Non-current Investments	-3944.84	-1664.10	-4386.48	-1664.12
	Net Cash Flow (Used in) Investing Activities (B)	-5502.39	-2168.79	-4563.06	-1970.63
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Add: Adjustment for				
	Proceeds from Issue of Equity Share Capital	156.03	68.70	156.03	68.70
	Increase in Securities Premium Reserve	6370.65	2012.91	6370.65	2012.91
	Decrease in short-term Borrowings	-1253.34	-	-1467.67	-
	Money received against Share warrants	2845.15	520.40	2845.15	520.40
	Principal payment of lease liability	-895.93	-423.26	-	-
	Interest payment of lease liability	-436.17	-162.09	-	-
	Dividend Paid	-	-	-	-
	Net Cash Flow from / (Used in) Financing Activities (C)	6786.39	2016.66	7904.15	2602.01
	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	131.15	69.92	34.44	41.03
	Opening Balance of Cash and Cash Equivalents	100.47	111.50	14.28	87.63
	Closing Balance of Cash and Cash Equivalents	231.62	181.42	48.72	128.66

The accompanying notes are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)
34, Ichhanath Umra,
Surat,


(Managing Director)
Moxesh K. Zota
(Din : 07625219)
8D, Lal Bunglow,
Surat,


Ashvin Variya
(Company Secretary)


Virat Madhivala
(Chief Financial Officer)



Date: 14-11-2024
Place: Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :


Zota House, 2/396, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

	healthcare ltd. Particulars	Standalone		Consolidated	
		As at	As at	As at	As at
		30th September, 2024 Unaudited	30th September, 2023 Unaudited	30th September, 2024 Unaudited	30th September, 2023 Unaudited
	ASSETS				
(1)	Non-Current Assets				
	Property, plant and equipment	756.79	822.20	3747.34	1639.40
	Right-of-use assets	-	-	9552.30	4706.83
	Intangible Assets	409.36	411.93	426.75	411.93
	Capital work-in-progress	491.26	420.45	491.26	420.45
	Intangible assets under development	-	-	-	-
	Financial Assets				
	(i) Investments	5063.49	2617.99	4414.78	2417.48
	(iii) Loans	2235.94	1307.47	11.02	11.02
	Deferred tax assets (Net)	17.47	-11.17	584.79	143.38
	Other Non-current assets	-	-	-	-
	Total Non-Current assets	8974.31	5568.87	19228.24	9750.49
(2)	Current Assets				
	Inventories	3381.72	2902.81	6468.06	3570.42
	Financial Assets				
	(i) Trade Receivables	11106.61	5776.77	2888.83	3225.62
	(ii) Cash and Cash Equivalents	0.17	1.66	156.82	24.24
	(iii) Bank balance other than cash and cash equivalents	48.55	127.00	74.80	157.18
	(iv) Loans	2593.71	692.10	1441.43	995.16
	Other Current Assets	350.99	90.86	1409.63	676.92
	Total Current assets	17481.76	9591.21	12439.57	8649.55
	Total Assets	26456.07	15160.08	31667.81	18400.04
	EQUITY AND LIABILITIES				
(1)	Equity				
	(i) Equity Share capital	2740.76	2584.73	2740.76	2584.73
	(ii) Other Equity	19223.22	9683.21	13158.86	7624.07
	Non-controlling Interest	-	-	346.00	-
	Total Equity	21963.98	12267.94	16245.62	10208.80
(2)	Liabilities				
	Non-Current Liabilities				
	Financial Liabilities				
	(i) Borrowings	-	-	-	-
	(ii) Lease liabilities	-	-	8021.86	5044.48
	Provisions	153.07	118.50	254.83	128.23
	Total non-current liabilities	153.07	118.50	8276.70	5172.71
	Current liabilities				
	Financial Liabilities				
	(i) Borrowings	-	-	214.34	-
	(ii) Lease liabilities	-	-	2440.04	-
	(ii) Trade payables	-	-	-	-
	- Total outstanding dues of micro enterprises and small enterprises	648.29	51.99	648.29	51.99
	- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	2851.74	1481.07	2355.49	1646.93
	Other Current liabilities	232.98	757.22	299.07	778.08
	Provisions	606.00	483.37	1188.27	541.52
	Total current liabilities	4339.02	2773.64	7145.50	3018.52
	Total Liabilities	4492.09	2892.14	15422.19	8191.23
	Total Equity and Liabilities	26456.07	15160.08	31667.81	18400.04

For and on behalf of the Board


(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)


(Managing Director)
Moxesh K. Zota
(Din : 07625239)


Company Secretary
Ashvin Variya


Chief Financial Officer
Viral Mandviwala

Date: 14-11-2024
Place : Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/396, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000OPLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122